Log in
NASDAQ:MDWD

Mediwound Stock Forecast, Price & News

$3.84
+0.13 (+3.50 %)
(As of 09/29/2020 12:00 AM ET)
Add
Compare
Today's Range
$3.62
Now: $3.84
$3.85
50-Day Range
$3.09
MA: $3.48
$3.91
52-Week Range
$1.44
Now: $3.84
$4.44
Volume43,748 shs
Average Volume110,941 shs
Market Capitalization$104.49 million
P/E RatioN/A
Dividend YieldN/A
Beta1.63
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Read More
Mediwound logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.35 out of 5 stars


Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MDWD
CUSIPN/A
Phone972-8932-4010

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.79 million
Cash Flow$0.14 per share
Book Value$0.56 per share

Profitability

Net Income$4.95 million

Miscellaneous

Employees73
Market Cap$104.49 million
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
$3.84
+0.13 (+3.50 %)
(As of 09/29/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MDWD News and Ratings via Email

Sign-up to receive the latest news and ratings for MDWD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Mediwound (NASDAQ:MDWD) Frequently Asked Questions

How has Mediwound's stock price been impacted by COVID-19?

Mediwound's stock was trading at $2.31 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MDWD stock has increased by 66.2% and is now trading at $3.84.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Mediwound?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mediwound in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Mediwound
.

When is Mediwound's next earnings date?

Mediwound is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Mediwound
.

How were Mediwound's earnings last quarter?

Mediwound Ltd (NASDAQ:MDWD) issued its quarterly earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, hitting the consensus estimate of ($0.11). The biopharmaceutical company had revenue of $4.03 million for the quarter, compared to the consensus estimate of $4.79 million. Mediwound had a negative return on equity of 85.28% and a negative net margin of 48.34%.
View Mediwound's earnings history
.

What price target have analysts set for MDWD?

3 brokerages have issued 12-month price targets for Mediwound's shares. Their forecasts range from $5.50 to $7.00. On average, they expect Mediwound's stock price to reach $6.17 in the next twelve months. This suggests a possible upside of 60.6% from the stock's current price.
View analysts' price targets for Mediwound
.

Are investors shorting Mediwound?

Mediwound saw a drop in short interest during the month of September. As of September 15th, there was short interest totaling 111,600 shares, a drop of 18.9% from the August 31st total of 137,600 shares. Based on an average trading volume of 139,100 shares, the days-to-cover ratio is presently 0.8 days. Approximately 0.5% of the company's stock are sold short.
View Mediwound's Short Interest
.

Who are some of Mediwound's key competitors?

What other stocks do shareholders of Mediwound own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mediwound investors own include Opko Health (OPK), Sorrento Therapeutics (SRNE), Blackstone Group (BX), Dynavax Technologies (DVAX), Geron (GERN), Idera Pharmaceuticals (IDRA), Mastercard (MA), SCYNEXIS (SCYX), Vascular Biogenics (VBLT) and Wells Fargo & Company (WFC).

Who are Mediwound's key executives?

Mediwound's management team includes the following people:
  • Mr. Gal Cohen, Pres & CEO (Age 46)
  • Prof. Lior Rosenberg, Co-Founder & Chief Medical Technology Officer (Age 73)
  • Mr. Sharon Malka CPA, MBA, Chief Financial & Operation Officer (Age 47)
  • Mr. Carsten Henke, Chief Commercial Officer of Europe (Age 53)
  • Dr. Ety Klinger, Chief R&D Officer (Age 57)

What is Mediwound's stock symbol?

Mediwound trades on the NASDAQ under the ticker symbol "MDWD."

How do I buy shares of Mediwound?

Shares of MDWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Mediwound's stock price today?

One share of MDWD stock can currently be purchased for approximately $3.84.

How big of a company is Mediwound?

Mediwound has a market capitalization of $104.49 million and generates $31.79 million in revenue each year. The biopharmaceutical company earns $4.95 million in net income (profit) each year or $0.08 on an earnings per share basis. Mediwound employs 73 workers across the globe.

What is Mediwound's official website?

The official website for Mediwound is www.mediwound.com.

How can I contact Mediwound?

Mediwound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company can be reached via phone at 972-8932-4010 or via email at [email protected]

This page was last updated on 9/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.